“Latest mid-to-late-stage trial will enroll 1,140 non-hospitalized adults diagnosed with coronavirus infection who are not at risk of severe illness. Patients in the trial will be given Pfizer's pill, known as PF-07321332, and a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection,” Pfizer state. The new drug is designed to block key enzyme’s activity to stop the multiplication of coronavirus.
Merck has also begun a new trial that “will study experimental drug molnupiravir for the prevention of COVID-19 among adults in the same household as someone diagnosed with symptomatic coronavirus infection. Merck and partner Ridgeback Biotherapeutics are already conducting a late-stage trial of the treatment in non-hospitalized patients to see if it reduces the risk of hospitalization or death.”
“Molnupiravir is a type of antiviral designed to introduce errors into the RNA of the virus that eventually prevent it from replicating,” Reuters explains.
As it was reported earlier, students from the University of Michigan found 17 medications that are effective against coronavirus.
In July, the Japanese pharmaceutical company Shionogi to test on people a drug used to treat coronavirus.